The role of p53, bcl-2 and bax network in dexamethasone induced apoptosis in multiple myeloma cell lines

International Journal of Oncology

Volumn 8, Issue 4, 1996, Pages 719-726

  Tian, Erming ^a   Gazitt, Yair ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Apoptosis; bax; bcl 2; DEX; p53

Indexed keywords

DEXAMETHASONE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029987106     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.8.4.719     Document Type: Article

References (60)

1. Cohen JJ: Overview: Mechanism of apoptosis. Immunol Today 14: 126-130, 1993.
2. Cohen JJ and Duke RC: Apoptosis and programmed cell death in immunity. Annu Rev Immunol 10: 267-293, 1992.
3. Marin MC, Hsu B, Meyn RE, Donehower LA, El-Naggar LK, and McDonnell TJ: Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphogenesis. Oncogene 9: 3107-3112, 1994.
4. Merino R, Ding L, Veis DJ, Korsmeyer SJ and Nunez G: Developmental regulation of the bcl-2 protein and susceptibility to cell death in B lymphocytes. EMBO J 13: 683-691, 1994.
5. Arends MJ and Wyllie AH: Apoptosis: Mechanism and role in Pathology. Int Rev Exp Pathol 32: 223-254, 1991.
6. Brown DG, Sun M-X and Cohen J: Dexamethasone induced apoptosis involves cleavage of DNA to large fragments prior to internucleosomal fragmentation. J Biol Chem 268: 3037-3039, 1993.
7. Lotem J and Sachs L: Regulation by bcl-2, c-myc, and p53 of susceptibility to induced apoptosis by heat-shock and cancer chemotherapy compounds in differentiation competent and defective myeloid leukemia. Cell Growth Different 4: 41-47, 1993.
8. Askew DS, Ashmun RA, Simmons BC and Cleveland JL: Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922, 1991.
9. Colombel M, Olsson CA, Ng PY and Buttyan R: Hormone regulated apoptosis results from reentry of differentiated prostate cells onto a defective cell cycle. Cancer Res 52: 4313-4319, 1992.
10. Bursch W, Oberhammar F, Jirtle RL, Askari M, Sedivy R, Grasl-Kraupp B, Purchio AF and Schulte-Herman R: Transforming growth factor beta as a signal for induction of cell death by apoptosis. Br J Cancer 67: 531-536, 1993.
11. Takayama S, Cazals-Hatem DL, Kitada S, Tanaka S, Miashita T, Hovey RL, Huen D, Rickinson A, Veerapandian P, Krajewski S, Saito K and Reed JC: Evolutionary conservation of function among mammalian, avian, and viral homologs of the bcl-2 oncoprotein. DNA Cell Biol 13: 679-692, 1994.
12. Hengartner MO, Horvitz HR: C. Elegans cell survival gene, ced-9 encodes a functional homolog of the mammalian bcl-2. Cell 76: 665-676, 1994.
13. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 53: 4701-4714, 1993.
14. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 80: 879-886, 1992.
15. Tsujimoto Y, Crossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1442, 1985.
16. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Bolch CA and Castle VP: Bcl-2 inhibits Chemotherapy induced apoptosis in neuroblastoma. Cancer Res 54: 3253-3259, 1994.
17. Reed JC, Kitada S and Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: s61-s65, 1994.
18. Allsop TE, Wyatt S, Paterson HF and Davis AM: The protooncogene bcl-2 can selectively rescue neurotrophic factor-dependent neurons from apoptosis. Cell 73: 295-307, 1993.
19. Strasser A, Harris AW, Jacks T and Croy S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanism inhibitable by bcl-2. Cell 79: 329-339, 1994.
20. Torigoe T, Millan JA, Takayama S, Taichman R, Miashita T and Reed JC: Bcl-2 inhibits T-cell mediated cytolysis of a leukemia cell line. Cancer Res 54: 4851-4854, 1994.
21. Bissonnette RP, Echeverri F, Mahboubi A and Green DR: Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359: 552-554, 1992.
22. Chio S-K, Rao L and White E: Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 14: 2556-2563, 1994.
23. Hockenbery DM: Bcl-2 in cancer, developement and apoptosis. J Cell Sci 18: 51-55, 1994.
24. Reed JC: Bcl-2 and programmed cell death. J Biol Chem 124: 16, 1994.
25. Hawkins CJ, Vaux DL: Analysis of the role of bcl-2 in apoptosis. Immunol Rev 142: 127-139, 1994.
26. Oltvai ZN: Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a homolog, bax, that accelerates programmed cell death. Cell 74: 609-619, 1993.
27. Yin X-M, Oltvai ZN and Korsmeyer SJ: BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 369: 321-323, 1994.
28. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Nordling S and Reed JC: Reduced expression of proapoptotic gene bax is associated with poor response rate to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
29. Zhan Q, Fan S, Bae I, Guillouf C, Lieberman DA, O'Connor PM and Fornace AJ: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751, 1994.
30. Miashita T, Harigai M, Hanada M, Reed JC: Identification of a p53 negative response element in the bcl-2 gene. Cancer Res 54: 3131-3135, 1994.
31. Miashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Lieberman DA, Hoffman B and Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
32. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
33. Korsmeyer SJ: Regulators of cell death. TIG 11: 101-105, 1995.
34. Hermine O, Haioun C, Lepage E, d'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marolleau J-P, Diebold J, Reyes F and Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87: 265-272, 1996.
35. Gazitt Y, Lee J-H, Tian E, Grove C, Barlogie B and Tricot G: Bcl-2 and not bax protein is the rate limiting step in dexamethasone induced apoptosis in myeloma cells. Exp Hematol 23: 289a, 1995.
36. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y and Nilson K: Expression of bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79: 495-502, 1992.
37. Ong F, Nieuwkoop JV, de Groot-Swings GMJS, Hermans J, Harvey MS, Kluin PhM and Kluin-Nelemans JC: Bcl-2 protein expression is not related to short survival in multiple myeloma. Leukemia 9: 1282-1284, 1995.
38. Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J: Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 84: 3063-3070, 1994.
39. Chen Y-S, Desai P, Shiao R-T, Lavelle D, Haleem A and Chen J: Inhibition of myeloma cell growth by dexamethasone and all trans retinoic acid: Synergy through modulation of interleukin-6 autocrine loop at multiple site. Blood 87: 314-323, 1996.
40. Lichtenstein A, Tu Y, Fady C, Vescio R and Berenson J: Interleukin-6 inhibits apoptosis in malignant plasma cells. Cell Immunol 162: 248-255, 1995.
41. Schwarze MMK and Hawley RG: Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin-6 mediated upregulation of bcl-x. Cancer Res 55: 2262-2265, 1995.
42. Gazitt Y, La Via M and Erdos GW: Regulation of growth and apoptosis in synchronized AGF cells: Involvement of oncogenes and cell cycle regulatory proteins. Int J Oncol 3: 489-496, 1993.
43. Gazitt Y and Erdos GW: Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 54: 950-956, 1994.
44. Gazitt Y, Reading CC, Hoffman R, Lee J-H, Barlogie B, Vesole D, Jagannath S, Condono J, Lee B, Wickerma A and Tricot G: Purified CD34+Lin-Thy+ stem cells do not contain myeloma cells. Blood 86: 381-389, 1995.
45. Portier M, Moles J-P, Mazars G-R, Jeanteur P, Bataille R, Klein B and Theillet C: p53 and ras mutations in multiple myeloma. Oncogene 7: 2539-2543, 1992.
46. Alderson LM, Castelberg RL, Harsh GR, Louis DN and Henson JW: Human Gliomas with wild-type p53 express bcl-2. Cancer Res 55: 999-1001, 1995.
47. Durie BMG, Young LA and Salmon SE: Human myeloma in vitro colony growth: interrelationship between drug-sensitivity, cell kinetics, and patient survival duration. Blood 61: 929-934, 1983.
48. Chen Y, Feng X-X and Schilder L: Effect of vincristine, adriamycin and glucocorticosteroids on myeloma cells in vitro. Acta Hematol 89: 61-66, 1993.
49. Tobler A, Meier R, Seitz M, Dewald B, Baggiolini M and Fay MF: Glucocorticoid down-regulate gene expression of GM-CSF, IL-8, and IL-6, but not M-CSF, in human fibroblasts. Blood 79: 45-51, 1992.
50. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M and Kuramoto A: Effect of glucocorticoids on the biologic activities of myeloma cells: Inhibition of IL-1 beta osteoclast activating factor-induced bone resorption. Blood 75: 715-720, 1990.
51. Miyashita T and Reed JC: Bcl-2 oncoprotein blocks chemotherapy induced apoptosis in human leukemia cell line. Blood 81: 151-157, 1993.
52. Smets LA, Van den Berg J, Acton D, Top B, Van Rooij H and Verwijs-Janssen M: Bcl-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 84: 1613-1619, 1994.
53. Alnemri ES, Fernandez TF, Haldar S, Croce CM and Litwak G: Involvement of bcl-2 in glucocorticoid-induced apoptosis in human pre-B leukemia. Cancer Res 52: 491-495, 1992.
54. Bornkamm GW and Richter C: A link between the anti-oxidant defense system and calcium: A proposal for the biochemical function of bcl-2. Current Topics Microbiol Immunol 194: 323-330, 1995.
55. Caron-Leslie LM, Evans RB and Cidlowski JA: Bcl-2 inhibits glucocorticoid-induced apoptosis but only partially blocks calcium ionophore or cycloheximide-regulated apoptosis in S 49 cells. FASEB J 8: 640-645, 1994.
56. Yan C and Faller DV: Direction of P21-generated signals towards cell growth or apoptosis is determind by protein kinase C and bcl-2. Oncogene 10: 1487-1498, 1995.
57. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, Mellstedt H and Einhorn S: Response to interferon therapy in patients with multiple myeloma correlates with expression of the bcl-2 oncoprotein. Int J Cancer 63: 190-192, 1995.
58. Campos L, Sabido O, Rouault J-P and Guyotat D: Effects of bcl-2 antisense oligonucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 84: 595-600, 1994.
59. Kitada S, Takayama S, de Riel K, Tanaka S and Reed JC: Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 4: 71-79, 1994.
60. Cotter FE, Johnson P, Hall P, Pocock C, Al Mahdi N, Cowel JK and Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 9: 3049-3055, 1994.